In the News

OSP was delighted to speak to Galina Nesterova, executive medical director at the Rare Disease & Pediatrics Center of Excellence, and Susan McCune, vice president of pediatrics and clinical pharmacology both within medical science and strategy at PPD, part of Thermo Fisher. They answered some pertinent questions surrounding rare diseases.

Paul Gillard provides an overview of vaccine mega-trials conducted over the last 20 years.

Lauren Herring discusses the comprehensive and robust centralized and one-to-one patient support that characterizes patient concierge services.

Lloryn Hubbard discusses how life science companies can address the disparities within clinical trials and health equity.

Dirk Reitsma notes that oncology studies have additional challenges compared to the many barriers to achieving diversity of populations in all clinical trials.

Jai Balkissoon and Evan Zynda highlight the key trends and challenges in cell and gene therapy, and explore the latest advancements in cell therapy for cancer treatment.

Our experts describe an intelligent drug development paradigm that enables small pharma to implement a truth-seeking early development approach like those used by progressive big pharma companies.

Robert King explains that solutions are on the horizon that will help overcome the current bottlenecks and other challenges that are occurring in early drug development.

Rose Blackburne discusses health equity and racial bias in pharma and how to address inequities in access and care.